+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 65 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of ACR-368, either alone or combined with ultra-low dose gemcitabine ULDG sensitization, in adults with high-grade endometrial cancer. This Phase 2 open-label study divides participants into four groups based on tumor characteristics and prior test results to better understand treatment responses. Participants are assigned to one of four groups two based on tumor sensitivity predicted by the OncoSignature test, and two without this selection. Those in Arms 1 and 4 receive ACR-368 alone, while Arms 2 and 3 receive ACR-368 combined with ULDG sensitization. Treatment continues until disease progression, unacceptable side effects, or withdrawal. During the study, participants undergo tumor response assessments every 8 weeks for up to 2 years or until death. Safety is monitored through adverse event tracking and limited pharmacokinetic testing. Researchers also observe overall survival, duration of response, and progression-free survival throughout the follow-up period ending at 2 years.

Age: 18Years +FEMALEPhase 2
90 locations
E

Actively Recruiting

Researchers are evaluating immunotherapies alone or combined with other drugs to delay or prevent colorectal cancer from returning in patients who are ctDNA-positive after their treatment. The study focuses on patients with colorectal cancer who have minimal residual disease following surgery and chemotherapy. This Phase II platform study investigates the drugs cemiplimab, fianlimab, and REGN7075 to understand their impact on cancer recurrence. Participants receive one of three treatments cemiplimab alone, cemiplimab with fianlimab, or cemiplimab with REGN7075. These drugs are given intravenously at specified doses. Eligible patients are confirmed ctDNA-positive through commercial assays and undergo treatment after definitive surgery and chemotherapy. This study runs from enrollment through multiple follow-up periods to assess the treatments effects. During the study, participants are monitored for clearance of ctDNA from enrollment to 12 weeks and for sustained clearance up to 18 months. Researchers also assess recurrence-free survival and safety during treatment and up to about 425 days after therapy. Blood tests, imaging, and clinical evaluations are part of the assessments to track participant health and treatment response over up to three years.

Age: 18Years +All GendersPhase 2
13 locations
C

Actively Recruiting

Researchers are comparing two treatment combinations for adults with advanced nonsquamous non-small cell lung cancer NSCLC that is stage IV or advanced stage IIIBC, specifically with a KRAS p.G12C mutation and no PD-L1 expression. The study evaluates progression-free survival and overall survival between participants receiving sotorasib with chemotherapy and those receiving pembrolizumab with chemotherapy. This is a phase 3, randomized, open-label study aiming to find which frontline therapy might better manage this type of lung cancer. Participants are randomly assigned to one of two groups one group receives sotorasib orally combined with carboplatin and pemetrexed chemotherapy, and the other group receives pembrolizumab given intravenously combined with the same chemotherapy agents. Treatments are given as front-line therapy for their cancer. The study measures the effects of these combinations over time, including tumor response and quality of life changes. During the study, participants will be closely monitored for progression-free survival, overall survival, and other outcomes related to tumor response and quality of life through questionnaires. Researchers will track treatment-emergent adverse events, vital signs, and lab tests to evaluate safety. The study includes follow-up assessments for up to approximately 5.5 years, allowing comprehensive evaluation of long-term outcomes and side effects. Participant involvement includes regular visits for treatment administration and assessments throughout the study period.

Age: 18Years - 100YearsAll GendersPhase 3
424 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of divarasib combined with pembrolizumab compared with pembrolizumab plus pemetrexed and carboplatin or cisplatin for adults with KRAS G12C-mutated, advanced or metastatic non-squamous non-small cell lung cancer NSCLC who have not received prior treatment. This phase 3 randomized study aims to find the best first-line therapy option for this specific lung cancer type. Participants are randomly assigned to one of two groups one group receives divarasib orally once daily and pembrolizumab through intravenous infusion every three weeks, while the other group receives pembrolizumab, pemetrexed, and carboplatin or cisplatin all by intravenous infusion every three weeks. The study treatments are given as first-line therapy, and participants are monitored for up to approximately five years. During the study, participants undergo regular assessments including scans to measure tumor response, evaluations of lung cancer symptoms like cough and breathlessness, quality of life questionnaires, and monitoring for side effects. Researchers track progression-free survival and overall survival for up to about five years. Safety and symptom severity are closely followed throughout the study, providing comprehensive data on treatment impact and participant well-being.

Age: 18Years +All GendersPhase 3
288 locations
R

Actively Recruiting

Researchers are studying whether adding JNJ-90301900 to standard treatment with platinum-based chemotherapy and radiation therapy, followed by consolidation immunotherapy, can improve the rate of tumor shrinkage in people with locally advanced, unresectable stage III non-small cell lung cancer. This is a phase 2 randomized trial aiming to assess the feasibility, safety, and effectiveness of JNJ-90301900 injections combined with the usual treatments. Participants are randomly assigned to receive JNJ-90301900 injected directly into tumors or lymph nodes at different doses along with concurrent chemotherapy and radiation therapy, followed by immunotherapy with durvalumab. Another group receives the standard concurrent chemoradiation followed by durvalumab without JNJ-90301900 to compare outcomes. Chemotherapy includes carboplatin and paclitaxel delivered intravenously, and radiation is given by intensity modulated radiation therapy. Throughout the study, participants undergo assessments of tumor response using imaging and clinical evaluations over up to two years. Researchers monitor safety through physical exams, lab tests, and recording adverse events. The main outcome is the objective response rate, measuring how many participants experience tumor shrinkage. Secondary outcomes include progression-free survival, duration of response, and other disease control measures. Participants will be followed for up to two years and two months to evaluate treatment effects and safety.

Age: 18Years +All GendersPhase 2
45 locations
P

Actively Recruiting

This research evaluates tolododekin alfa also known as ANK-101 combined with an anti-PD-1PD-L1 antibody in people with advanced or metastatic non-small cell lung cancer NSCLC. It includes two groups one with participants who have progressed after prior standard treatments including anti-PD-1PD-L1 antibodies and chemotherapy, and another with participants who have not yet received treatment for locally advanced or metastatic NSCLC. Participants receive up to 8 cycles of tolododekin alfa administered as an intratumoral injection every 3 weeks. They also receive either cetrelimab or the investigators choice of an FDA-approved anti-PD-1PD-L1 antibody, both given every 3 weeks, for up to 1 year. The study compares these combinations in two parallel cohorts based on previous treatment history. Throughout the study, participants undergo assessments including tumor response evaluation using RECIST v1.1 criteria, safety monitoring for adverse events, and pharmacokinetic measurements of tolododekin alfa. Researchers measure outcomes like objective response rate, duration of response, disease control, progression-free survival, and overall survival over six months. Participants must provide fresh tumor biopsies and comply with study requirements during the treatment period, which may last up to one year.

Age: 18Years +All GendersPhase 1
11 locations
T

Actively Recruiting

Researchers are studying the use of Trastuzumab Deruxtecan T-DXd as an adjuvant treatment compared to standard chemotherapy, with or without radiotherapy, in women with newly diagnosed HER2-expressing endometrial cancer. This phase 3, open-label global trial aims to assess the safety and effectiveness of these treatments in participants who have not previously received anticancer therapy. The study focuses on participants with specific stages and various levels of HER2 expression in their cancer. Participants will be randomly assigned to receive either T-DXd at a dose of 5.4 mgkg intravenously every three weeks, with optional radiotherapy, or standard chemotherapy consisting of carboplatin and paclitaxel given every three weeks, with or without radiotherapy or chemoradiotherapy including cisplatin as a radiosensitizer. This comparison will evaluate how well these treatments work as adjuvant therapy following surgery. The study will continue until disease recurrence or other defined endpoints. During the study, participants will be monitored for disease-free survival using imaging reviewed by a blinded independent central review or local histopathologic confirmation, up to about 51 months after randomization. Overall survival will also be tracked up to approximately 63 months. Assessments will include radiographic evaluations and safety monitoring. Participants can expect regular visits for treatment and follow-up over several years to measure outcomes and ensure safety throughout the trial period.

Age: 18Years +FEMALEPhase 3
86 locations
A

Actively Recruiting

Researchers are evaluating whether combining tucatinib with trastuzumab and mFOLFOX6 works better than standard treatments for people with HER2 positive colorectal cancer that has spread or cannot be removed by surgery. This Phase 3 study also aims to learn about the side effects that may occur when taking this combination of drugs. Participants have metastatic or unresectable colorectal cancer and are randomly assigned to different treatment groups. Participants are randomly placed in one of two study groups. One group receives tucatinib taken orally twice daily along with trastuzumab given intravenously every 3 weeks and mFOLFOX6 chemotherapy every 2 weeks. The other group receives standard care, which may be mFOLFOX6 alone or combined with bevacizumab or cetuximab, both given intravenously on different schedules. Tissue samples and biopsies are collected before treatment to confirm HER2 positivity and other markers. During the study, participants will have regular evaluations including imaging scans to measure cancer progression, blood tests, and assessments of side effects and quality of life. Progression-free survival is the primary outcome measured for up to about 3 years, with other outcomes like overall survival and response rate also tracked. Safety monitoring continues for about one year after the last treatment. The study lasts several years, with ongoing follow-up to understand long-term effects and benefits.

Age: 18Years +All GendersPhase 3
366 locations
E

Actively Recruiting

Researchers are evaluating the use of Vedolizumab in adults with moderate to severely active Ulcerative Colitis UC or Crohns Disease CD. These long-term gut conditions cause symptoms like diarrhea, inflammation, bleeding, and belly pain. The study aims to determine how many participants achieve remission, meaning their symptoms disappear, after 14 weeks of treatment. This is a Phase 4 treatment study sponsored by Takeda. Participants will receive Vedolizumab through two methods. For the first 6 weeks, they get 300 mg intravenously at weeks 0 and 2, with a possible additional dose at week 6. Afterward, starting by week 6 and definitely by week 14, the administration switches to 108 mg injections under the skin every 2 weeks until week 50. Participants who do not respond to treatment by week 14 will stop Vedolizumab and may switch to other treatments, with additional clinic visits at 26 and 52 weeks. A follow-up occurs 18 weeks after the last Vedolizumab dose. Throughout the study, participants have several clinic visits for treatments and assessments. Researchers will measure remission rates using patient-reported outcomes at weeks 6, 14, and 52, alongside clinical response, endoscopic results, and markers like C-reactive protein and fecal calprotectin. Safety is monitored by tracking serious infections up to 72 weeks. The total participation time spans about one year of treatment plus follow-up after treatment ends.

Age: 18Years - 80YearsAll GendersPhase 4
101 locations
E

Actively Recruiting

Researchers are evaluating the safety and changes in disease activity of different treatment combinations using mirvetuximab soravtansine with carboplatin, bevacizumab, or bevacizumab alone in adult women with ovarian cancer. This phase 2 study focuses on participants confirmed to have folate receptor alpha positive tumors through a specific assay. The purpose is to assess adverse events and treatment responses across multiple treatment groups. Participants will be assigned to one of three substudies, each with different treatment arms. Treatments involve intravenous infusions of mirvetuximab soravtansine combined with bevacizumab, carboplatin, or both, with dosing variations and sequences depending on the substudy. The study duration varies from approximately 31 to 40 months based on the treatment group and includes follow-up after initial combination therapies. During the study, participants will attend regular hospital or clinic visits for medical assessments including blood tests and scans. Researchers will monitor treatment-emergent adverse events, ocular adverse events, peripheral neuropathy, lung disease, and overall and progression-free survival using standardized criteria. The safety and effectiveness of the treatments will be tracked over the entire study period, which may require a higher treatment burden than standard care.

Age: 18Years +FEMALEPhase 2
86 locations

1-10 of 65

1